Biotech: Page 6

  • Desks line a darkened medical laboratory in this stock image.
    Image attribution tooltip
    Sean Anthony Eddy via Getty Images
    Image attribution tooltip
    Biotech zombies

    Cancer drugmaker iTeos to shut down

    Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid to "maximize" shareholder value.

    By • May 28, 2025
  • Histological sample Striated (Skeletal) muscle of mammal Tissue under the microscope.
    Image attribution tooltip
    Sinhyu via Getty Images
    Image attribution tooltip
    Obesity drugs

    Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

    The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

    By • May 28, 2025
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

    By BioPharma Dive staff
  • Behind the Breakthroughs: How Almac Powers Clinical Trial Success With Care – A partnership with BioPharma Dive, highlighting Almac’s commitment to patient-centric clinical trial support.
    Image attribution tooltip
    Kerianne Condon/BioPharma Dive
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care

    Agile biopharma firms are driving breakthroughs. Learn how they ensure clinical trial success in this podcast.

    By BioPharma Dive's studioID • May 28, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    Biogen strikes RNAi deal with City; Aurion withdraws IPO

    City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.

    By BioPharma Dive staff • May 27, 2025
  • A cardiac tissue sample viewed through a microscope.
    Image attribution tooltip
    Sinhyu via Getty Images
    Image attribution tooltip

    Patient dies in trial of Rocket gene therapy for heart condition

    The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause of the patient’s death.

    By • May 27, 2025
  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Pla2Na via Getty Images
    Image attribution tooltip

    GlycoEra raises $130M, riding interest in protein degraders

    The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach drug targets other technologies can’t.

    By • May 27, 2025
  • A scientist in a lab on their laptop
    Image attribution tooltip

    iStockPhoto / Jacob Wackerhausen

    Image attribution tooltip
    Sponsored by Sapio Sciences

    The transformative impact of integrated informatics platforms on biopharma R&D

    Integrated informatics platforms boost R&D speed, data quality and ROI across BioPharma

    By Nicola Brookman-Amissah, PhD • May 27, 2025
  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    aprott via Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo pressures GLP-1 compounders as FDA ban takes hold

    The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.

    By Kristin Jensen • May 22, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

    An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs bought a startup.

    By BioPharma Dive staff • May 22, 2025
  • Spermatozoon is injected into an ovum with help of microneedle and holding pipette underneath a microscope
    Image attribution tooltip
    Svitlana Hulko via Getty Images
    Image attribution tooltip

    Reproductive health startup raises $65M for infertility drugs

    Founded in 2021, ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in men and women.

    By • May 21, 2025
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Vaccines

    Moderna pulls application for combo COVID, flu shot

    The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from yesterday.

    By • May 21, 2025
  • A sign spelling Roche hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip

    Roche strikes second Orionis deal to develop ‘molecular glues’ for cancer

    The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body of destructive proteins that are hard to target by other means.

    By Kristin Jensen • May 21, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

    Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

    By BioPharma Dive staff • May 20, 2025
  • A person in a white shirt sits in an office for a photograph.
    Image attribution tooltip
    Permission granted by Prime Medicine
    Image attribution tooltip
    Gene editing

    Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

    CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead program.

    By • May 19, 2025
  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images
    Image attribution tooltip
    Vaccines

    Novavax’s COVID vaccine gets FDA approval, but with limits

    While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

    By • May 19, 2025
  • 23andMe
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Regeneron wins bid to buy 23andMe out of bankruptcy

    The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

    By • May 19, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

    A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

    By • May 16, 2025
  • A swaddled infant in a hospital bassinet smiles.
    Image attribution tooltip
    Permission granted by Muldoon family
    Image attribution tooltip

    A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases

    A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months. 

    By • May 15, 2025
  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA delays approval decision for Biohaven rare disease drug

    Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an outside group of advisers to evaluate it as well.

    By • May 15, 2025
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie stakes $335M on a startup’s RNAi drugs

    ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer. 

    By • May 15, 2025
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Magdalena Wygralak via Getty Images
    Image attribution tooltip

    GSK to buy liver disease drug for $1.2B

    With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

    By Kristin Jensen • May 14, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    Bluebird extends deal deadline; Affimed files for insolvency

    Shareholders in Bluebird now have a choice of two offers from would-be acquirers Carlyle and SK Capital. Elsewhere, Cytokinetics shared more aficamten data and BridgeBio started a new kind of Attruby trial.

    By BioPharma Dive staff • May 14, 2025
  • The entrance to Galapagos' corporate offices are lit up at dusk.
    Image attribution tooltip
    Courtesy of Galapagos
    Image attribution tooltip

    Galapagos backtracks on planned split

    Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic options and “transformative” deals.

    By • May 13, 2025
  • MRI images of the lungs are back lit on a screen for review
    Image attribution tooltip
    Bunyos via Getty Images
    Image attribution tooltip

    iTeos, GSK to shelve TIGIT drug after study setback

    The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response. 

    By • May 13, 2025
  • multiple syringes with pink liquid filling up capsules directly below
    Image attribution tooltip
    Courtesy of https://valneva.com/media-kit/
    Image attribution tooltip

    FDA follows EMA in limiting use of Valneva shot

    Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and now the U.S. to suspend use in older adults pending an investigation.

    By • May 12, 2025